Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Quinazoline. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel synthetic route for Gefitinib intermediates utilizing cheap raw materials, mild conditions, and avoiding toxic chlorinating agents for cost-effective production.
Novel 2-phenyl quinazoline derivatives targeting telomerase with high selectivity and low toxicity. Efficient synthesis routes for pharmaceutical intermediates.
Optimized Gefitinib preparation method ensures high purity and reduced environmental impact for scalable API manufacturing supply chains.
Novel one-step synthesis of 5-bromoquinazoline derivative (CN112300178A). Offers catalytic utility and anticancer potential with streamlined production.
Advanced synthesis of heteroaromatic quinazoline derivatives via patent CN101663303A. Delivers high-purity pharmaceutical intermediates with optimized supply chain reliability.
Novel route for 3-amino-6-(perfluoropropane-2-yl)-3,4-dihydroquinazolin-2(1H)-one offering high purity and cost efficiency for insecticide production.
Novel FeCl3-catalyzed reduction and Mitsunobu coupling route for AZD3759 intermediate. Reduces steps, eliminates POCl3, lowers cost for pharma manufacturing.
Patent CN102153519B reveals a mild peptide coupling route for Gefitinib intermediates, offering cost reduction in API manufacturing and enhanced supply chain reliability.
Novel rhodium-catalyzed method enables high-purity quinazoline production with reduced costs and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN106632086B details a Rhodium-catalyzed C-H iodination method for quinazolines. This process offers high purity, mild conditions, and significant cost reduction in pharmaceutical intermediate manufacturing.
Patent CN109180592B details a green synthesis of 7-chloro-2-(3-chlorophenyl)quinazoline using NNN-Ru catalysts. Discover cost-effective, scalable manufacturing solutions.
Novel route for Gefitinib avoiding methanesulfonic acid demethylation, offering cost-effective API intermediate manufacturing solutions.
Patent CN102627614B details a robust synthesis of bisquinazoline diselenides. This report analyzes cost-effective manufacturing and supply chain reliability for oncology intermediates.
Patent CN111704604B reveals a high-yield convergent route for pyridine quinazoline, offering significant cost reduction and supply chain reliability for agrochemical manufacturers.
Patent CN102675223B reveals a copper-catalyzed one-step synthesis for quinazolines. This method offers significant cost reduction and supply chain reliability for fine chemical manufacturing.
Patent CN110590780B reveals a novel copper-catalyzed route for Linagliptin intermediates, offering significant cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Patent CN111454222B reveals a metal-free CO2 fixation route for quinazolinediones. This method offers high yields, mild conditions, and significant cost reduction potential.
Novel patent CN104262265B details efficient synthesis of tetrahydroquinazoline derivatives offering significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel solid-phase method for EGFR inhibitors. High purity, scalable route for anticancer drug discovery intermediates.
Patent CN105111217A details copper-catalyzed one-pot synthesis offering high purity and efficient supply chain solutions for global pharmaceutical intermediate manufacturing partners.